DNLIHealthcare · BiotechnologyThe 20 Wall Street analysts covering Denali Therapeutics, Inc. hold a median 12-month price target of $35 — +75.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 3 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Denali Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (69): Analysts have, on balance, been raising their forecasts.
Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (29): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DNLI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +75.8% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Aug 2026 | B. Riley Securities | Maintains | Buy | $30 → $35 |
| 7 Aug 2026 | UBS | Maintains | Buy | — |
| 7 Aug 2026 | UBS | Maintains | Buy | $25 → $34 |
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | $35 → $36 |
| 23 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 16 July 2026 | Deutsche Bank | Maintains | Buy | $31 → $35 |
| 16 July 2026 | Deutsche Bank | Maintains | Buy | — |
| 13 July 2026 | JP Morgan | Reinstates | Overweight | $29 |
| 26 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 14 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 May 2026 | BTIG | Reiterates | Buy | — |
| 8 May 2026 | Wedbush | Maintains | Outperform | — |
| 22 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 7 Apr 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Baird | Maintains | Outperform | — |
| 26 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Mar 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Mar 2026 | Stifel | Maintains | Buy | — |
| 25 Mar 2026 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNLI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Oct 2026, Denali Therapeutics, Inc. returned +29.1% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 1% of US stocks
Cheaper than 26% of US stocks
Cheaper than 79% of US stocks
Higher than 99% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Denali Therapeutics, Inc. has a market value of $3.2B and an enterprise value of $2.5B.
Revenue in the twelve months to 30 June 2026: $3.6M.
Net income over the same four quarters: −$511.5M, a −14191.2% net margin.
Diluted earnings per share, trailing twelve months: $−2.84.
Free cash flow in the twelve months to 30 June 2026: −$466.3M.
Trailing P/E: −6.7×; forward P/E: −8.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Denali Therapeutics, Inc. employs 503 people — $7K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Denali Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Denali Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published on Seeking Alpha.
Why it matters — A transcript of the conference presentation gives Denali watchers direct insight into what the company communicated to investors and analysts at a major healthcare event.
Denali Therapeutics' stock rose 33.1% over three months, driven by strong uptake of its Avlayah launch. However, regulatory and pipeline risks remain for the company.
Why it matters — A DNLI watcher would care because the stock's recent gain is tied to the Avlayah launch, while ongoing regulatory and pipeline risks could affect the company's outlook.
AVLAYAH's approval has validated Denali Therapeutics' TransportVehicle platform, and the company is entering its commercial stage with early payer coverage and Q3 guidance supporting a credible launch ramp. The US label limits near-term potential, but zafinofusp alfa and four TV-enabled 2027 readouts offer pipeline upside.
Why it matters — A DNLI watcher would care because AVLAYAH's validation and upcoming 2027 pipeline readouts signal meaningful growth catalysts beyond the current label's limits.
Denali Therapeutics is shifting from a neuroscience platform to a commercial biotech with its FDA-approved rare-disease therapy AVLAYAH. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress.
Why it matters — This marks a key transition for DNLI as its AVLAYAH commercial launch and platform pipeline could shape its growth trajectory beyond the platform stage.
Denali Therapeutics narrowed its second-quarter loss, with Avlayah sales exceeding estimates and showing strong launch traction. The company also provided pipeline updates that are shaping its outlook.
Why it matters — A DNLI watcher would care because the narrowing loss and strong Avlayah launch momentum signal positive early commercial traction for the company's lead product.
The 20 Wall Street analysts covering Denali Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $27 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering Denali Therapeutics, Inc., 19 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Denali Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Oct 2026, Denali Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (69 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +75.8% from the last close, and Ticker Nerd's factor model ranks Denali Therapeutics, Inc. 56 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Denali Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNLI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $42 over the next 12 months.
Denali Therapeutics, Inc. returned +29.1% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases.
The most recent item we track (Seeking Alpha, 14 Sept 2026): "Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Denali Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published on Seeking Alpha.
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders. The company’s approach centers on delivering biologic and genetic medicines across the blood-brain barrier through its proprietary TransportVehicle platform, which is designed to improve access to hard-to-reach tissues in the central nervous system. Denali Therapeutics also works on product candidates across enzyme, oligonucleotide, and antibody-based programs, supporting a broader pipeline that targets both brain and body diseases. Headquartered in South San Francisco, California, Denali Therapeutics operates within the biotechnology sector and plays a role in the development of next-generation therapies for complex, high-unmet-need conditions.
CEO Dr. Ryan J. Watts Ph.D. · 503 employees · United States · https://www.denalitherapeutics.com
